Search

Your search keyword '"Finke, Christy"' showing total 918 results
Start Over Author "Finke, Christy"
918 results on '"Finke, Christy"'

208. Prognostic Impact of ASXL1 Mutations and Extent of Bone Marrow Dysplasia in Patients with Who - defined Myelodysplastic Syndrome with Ring Sideroblasts

Author

Mangaonkar, Abhishek, Lasho, Terra L., Finke, Christy, Gangat, Naseema, Al-Kali, Aref, Elliott, Michelle A., Begna, Kebede H., Alkhateeb, Hassan, Hanson, Curtis A., Ketterling, Rhett P., Wolanskyj, Alexandra, Hogan, William J., Pardanani, Animesh, Litzow, Mark R., Tefferi, Ayalew, and Patnaik, Mrinal M.

Published
2017
Full Text
View/download PDF

213. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.

Author

Zahid, Mohammad Faizan, Barraco, Daniela, Lasho, Terra L., Finke, Christy, Ketterling, Rhett P., Gangat, Naseema, Hanson, Curtis A., Tefferi, Ayalew, and Patnaik, Mrinal M.

Subjects
LEUKEMIA, AUTOIMMUNE diseases, SYSTEMIC inflammatory response syndrome, PATIENTS
Abstract

A letter to the editor is presented which discusses the study on the clinical spectrum and outcomes of autoimmune diseases (AID) and/or systemic inflammatory syndromes (SIS) in patients with chronic myelomonocytic leukemia (CMML).

Published
2017
Full Text
View/download PDF

214. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Author

Tefferi, Ayalew, Guglielmelli, Paola, Larson, Dirk R., Finke, Christy, Wassie, Emnet A., Pieri, Lisa, Gangat, Naseema, Fjerza, Rajmonda, Belachew, Alem A., Lasho, Terra L., Ketterling, Rhett P., Hanson, Curtis A., Rambaldi, Alessandro, Finazzi, Guido, Thiele, Juergen, Barbui, Tiziano, Pardanani, Animesh, Vannucchi, Alessandro M., Tefferi, Ayalew, Guglielmelli, Paola, Larson, Dirk R., Finke, Christy, Wassie, Emnet A., Pieri, Lisa, Gangat, Naseema, Fjerza, Rajmonda, Belachew, Alem A., Lasho, Terra L., Ketterling, Rhett P., Hanson, Curtis A., Rambaldi, Alessandro, Finazzi, Guido, Thiele, Juergen, Barbui, Tiziano, Pardanani, Animesh, and Vannucchi, Alessandro M.

Abstract

Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primarymyelofibrosis (PMF). We examined the effect of these mutations on long-term disease outcome. One thousand five hundred eighty-one patients from the Mayo Clinic (n = 826) and Italy (n = 755) were studied. Fifty-eight percent of Mayo patients were followed until death; median survivals were 19.8 years in ET (n = 292), 13.5 PV (n = 267; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.4-2.2), and 5.9 PMF(n = 267; HR, 4.5; 95% CI, 3.5-5.7). The survival advantage of ET over PV was not affected by JAK2/CALR/MPL mutational status. Survival in ET was inferior to the age-and sex-matched US population (P < .001). In PMF (n = 428), but not in ET (n = 576), survival and blast transformation (BT) were significantly affected by mutational status; outcome was best in CALR-mutated and worst in triple-negative patients: median survival, 16 vs 2.3 years (HR, 5.1; 95% CI, 3.2-8.0) and BT, 6.5% vs 25% (HR, 7.6; 95% CI, 2.8-20.2), respectively. We conclude that life expectancy in morphologically defined ET is significantly reduced but remains superior to that of PV, regardless of mutational status. In PMF, JAK2/CALR/MPL mutational status is prognostically informative.

Published
2014

217. Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Author

Patnaik, Mrinal M., primary, Wassie, Emnet A, additional, Padron, Eric, additional, Onida, Francesco, additional, Itzykson, Raphael, additional, Lasho, Terra L, additional, Kosmider, Olivier, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Ketterling, Rhett, additional, Komrokji, Rami S, additional, Tefferi, Ayalew, additional, and Solary, Eric, additional

Published
2014
Full Text
View/download PDF

220. Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Author

Tefferi, Ayalew, primary, LaPlant, Betsy R., additional, Begna, Kebede, additional, Patnaik, Mrinal M., additional, Lasho, Terra L, additional, Zblewski, Darci, additional, Finke, Christy, additional, Schimek, Lauren, additional, Pettinger, Adam, additional, Hanson, Curtis A., additional, Gangat, Naseema, additional, and Pardanani, Animesh, additional

Published
2014
Full Text
View/download PDF

225. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history

Author

Gangat, Naseema, primary, Wassie, Emnet A., additional, Lasho, Terra L., additional, Finke, Christy, additional, Ketterling, Rhett P., additional, Hanson, Curtis A., additional, Pardanani, Animesh, additional, Wolanskyj, Alexandra P., additional, Maffioli, Margherita, additional, Casalone, Rosario, additional, Passamonti, Francesco, additional, and Tefferi, Ayalew, additional

Published
2014
Full Text
View/download PDF

226. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Author

Tefferi, Ayalew, primary, Guglielmelli, Paola, additional, Larson, Dirk R., additional, Finke, Christy, additional, Wassie, Emnet A., additional, Pieri, Lisa, additional, Gangat, Naseema, additional, Fjerza, Rajmonda, additional, Belachew, Alem A., additional, Lasho, Terra L., additional, Ketterling, Rhett P., additional, Hanson, Curtis A., additional, Rambaldi, Alessandro, additional, Finazzi, Guido, additional, Thiele, Juergen, additional, Barbui, Tiziano, additional, Pardanani, Animesh, additional, and Vannucchi, Alessandro M., additional

Published
2014
Full Text
View/download PDF

227. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information

Author

Tefferi, Ayalew, Gangat, Naseema, Mudireddy, Mythri, Lasho, Terra L., Finke, Christy, Begna, Kebede H., Elliott, Michelle A., Al-Kali, Aref, Litzow, Mark R., Hook, C. Christopher, Wolanskyj, Alexandra P., Hogan, William J., Patnaik, Mrinal M., Pardanani, Animesh, Zblewski, Darci L., He, Rong, Viswanatha, David, Hanson, Curtis A., Ketterling, Rhett P., Tang, Jih-Luh, Chou, Wen-Chien, Lin, Chien-Chin, Tsai, Cheng-Hong, Tien, Hwei-Fang, and Hou, Hsin-An

Abstract

To develop a new risk model for primary myelodysplastic syndromes (MDS) that integrates information on mutations, karyotype, and clinical variables.

Published
2018
Full Text
View/download PDF

230. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Author

Tefferi, Ayalew, Guglielmelli, Paola, Nicolosi, Maura, Mannelli, Francesco, Mudireddy, Mythri, Bartalucci, Niccolo, Finke, Christy, Lasho, Terra, Hanson, Curtis, Ketterling, Rhett, Begna, Kebede, Gangat, Naseema, Pardanani, Animesh, and Vannucchi, Alessandro

Abstract

International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified “VHR” karyotype, “unfavorable” karyotype, absence of type 1/like CALRmutation and presence of ASXL1,SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95% CI) were 3.1 (2.1–4.3), 2.1 (1.6–2.7), 2.1 (1.6–2.9), 1.8 (1.5–2.3), 2.4 (1.9–3.2), and 2.4 (1.7–3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n= 58), intermediate-1 (1 point; n= 260), intermediate-2 (2 points; n= 192), and high (≥3 points; n= 131); the respective median (5-year) survivals were 26.4 (94%), 8.0 (73%), 4.2 (40%), and 2 (14%) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.

Published
2018
Full Text
View/download PDF

231. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Author

Lasho, Terra L., Mudireddy, Mythri, Finke, Christy M., Hanson, Curtis A., Ketterling, Rhett P., Szuber, Natasha, Begna, Kebede H., Patnaik, Mrinal M., Gangat, Naseema, Pardanani, Animesh, and Tefferi, Ayalew

Abstract

Among 248 consecutive patients with blast phase myeloproliferative neoplasm (MPN-BP), DNA collected at the time of blast transformation was available in 75 patients (median age, 66 years; 64% men). MPN-BP followed primary myelofibrosis in 39 patients, essential thrombocythemia in 20 patients, and polycythemia vera in 16 patients. A myeloid neoplasm–relevant 33-gene panel was used for next-generation sequencing. Driver mutation distribution was JAK2 57%, CALR 20%, MPL 9%, and triple-negative 13%. Sixty-four patients (85%) harbored other mutations/variants, including 37% with =3 mutations; most frequent were ASXL1 47%, TET2 19%, RUNX1 17%, TP53 16%, EZH2 15%, and SRSF2 13%; relative mutual exclusivity was expressed by TP53, EZH2, LNK, RUNX1, SRSF2, and NRAS/KRAS mutations. Paired chronic-blast phase sample analysis was possible in 19 patients and revealed more frequent blast phase acquisition of ASXL1, EZH2, LNK, TET2, TP53, and PTPN11 mutations/variants. In multivariable analysis, RUNX1 and PTPN11 mutations/variants were associated with shorter survival duration; respective hazard ratios (HRs) (95% confidence interval [CI]) were 2.1 (95% CI, 1.1-3.8) and 3.0 (95% CI, 1.1-6.6). An all-inclusive multivariable analysis confirmed the prognostic relevance of RUNX1 mutations (HR, 1.9; 95% CI, 1.5-5.5) and also showed additional contribution from a treatment strategy that includes transplant or induction of complete or near-complete remission (HR, 0.3; 95% CI, 0.2-0.5). The current study points to specific mutations that might bear pathogenetic relevance for leukemic transformation in MPN and also suggest an adverse survival effect of RUNX1 mutations.

Published
2018
Full Text
View/download PDF

234. Clonal Hematopoiesis in Vexas Syndrome

Author

Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Kusne, Yael, Fernandez, Jenna A., Lasho, Terra, Shalhoub, Ruba, Ma, Xiaoyang, Alessi, Hugh, Finke, Christy, Koster, Matthew, Mangaonkar, Abhishek A., Warrington, Kenneth, Begna, Kebede H., Xie, Zhuoer, Ombrello, Amanda, Viswanatha, David S., Ferrada, Marcela, Wilson, Lorena, Go, Ronald, Kourelis, Taxiarchis, Reichard, Kaaren K., Olteanu, Horatiu, Groarke, Emma M., Darden, Ivana, Hironaka, Dalton, Rosenzweig, Sofia, Kastner, Daniel L., Calvo, Katherine R., Wu, Colin O., Grayson, Peter C., Beck, David B., Patnaik, Mrinal M.M., and Young, Neal S.

Published
2022
Full Text
View/download PDF

237. DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways

Author

Fernandez, Jenna A., Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Kusne, Yael, Lasho, Terra, Finke, Christy, Koster, Matthew, Mangaonkar, Abhishek A., Gangat, Naseema, Warrington, Kenneth, Reichard, Kaaren K., Olteanu, Horatiu, Grayson, Peter C., Young, Neal S., Beck, David B., and Patnaik, Mrinal M.

Published
2022
Full Text
View/download PDF

238. DNMT3A/TET2Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1and MPLOncogenic Pathways

Author

Fernandez, Jenna A., Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Kusne, Yael, Lasho, Terra, Finke, Christy, Koster, Matthew, Mangaonkar, Abhishek A., Gangat, Naseema, Warrington, Kenneth, Reichard, Kaaren K., Olteanu, Horatiu, Grayson, Peter C., Young, Neal S., Beck, David B., and Patnaik, Mrinal M.

Published
2022
Full Text
View/download PDF

244. Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Author

Guglielmelli, Paola, primary, Lasho, Terra L., additional, Biamonte, Flavia, additional, Score, Johannah, additional, Mannarelli, Carmela, additional, Rotunno, Giada, additional, Pancrazzi, Alessandro, additional, Pardanani, Animesh, additional, Zoi, Katerina, additional, Reiter, Andreas, additional, Duncombe, Andrew, additional, Pietra, Daniela, additional, Rumi, Elisa, additional, Finke, Christy, additional, Gangat, Naseema, additional, Ketterling, Rhett P., additional, Knudson, Ryan A., additional, Laborde, Rebecca R., additional, Bosi, Alberto, additional, Pereira, Arturo, additional, Cervantes, Francisco, additional, Barosi, Giovanni, additional, Cazzola, Mario, additional, Cross, Nicholas C.P., additional, Tefferi, Ayalew, additional, and Vannucchi, Alessandro M., additional

Published
2013
Full Text
View/download PDF

247. Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Author

Pardanani, Animesh, primary, Abdelrahman, Ramy A, additional, Begna, Kebede, additional, Zblewski, Darci, additional, Al-Kali, Aref, additional, Patnaik, Mrinal M., additional, Hogan, William, additional, Lasho, Terra L, additional, Finke, Christy, additional, Hanson, Curtis A., additional, Litzow, Mark R., additional, and Tefferi, Ayalew, additional

Published
2013
Full Text
View/download PDF

250. Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Author

Tefferi, Ayalew, primary, Begna, Kebede, additional, Laborde, Rebecca R., additional, Patnaik, Mrinal M, additional, Lasho, Terra L, additional, Zblewski, Darci, additional, Finke, Christy, additional, Schimek, Lauren, additional, LaPlant, Betsy R., additional, Hanson, Curtis A., additional, Stuart, Monic J., additional, and Pardanani, Animesh, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results